Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration
Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions. Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025. DAEJEON, South Kore...